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Explaining national differences in the mortality of Covid-19: individual patient 
simulation model to investigate the effects of testing policy and other factors on 
apparent mortality. 
Jonathan A Michaels and Matt D Stevenson 
School of Health and Related Research, University of Sheffield, UK 
ABSTRACT 
There has been extensive speculation on the apparent differences in mortality between 
countries reporting on the confirmed cases and deaths due to Covid-19.  A number of 
explanations have been suggested, but there is no clear evidence about how apparent 
fatality rates may be expected to vary with the different testing regimes, admission 
policies and other variables.  An individual patient simulation model was developed to 
address this question.  Parameters and sensitivity analysis based upon recent 
international data sources for Covid-19 and results were averaged over 100 iterations 
for a simulated cohort of over 500,000 patients. 
Different testing regimes for Covid-19 were considered; testing admitted patients only, 
various rates of community testing of symptomatic cases and active contact-tracing and 
screening. 
In the base case analysis, apparent mortality ranged from 10.5% under a policy of 
testing only admitted patients to 0.4% with intensive contact tracing and community 
testing.  These findings were sensitive to assumptions regarding admission rates and 
the rate of spread, with more selective admission policies and suppression of spread 
increasing the apparent mortality and the potential for apparent mortality rates to exceed 
18% under some circumstances.  Under all scenarios the proportion of patients tested 
in the community had the greatest impact on apparent mortality. 
Whilst differences in mortality due to health service and demographic factors cannot 
be excluded, the current international differences in reported mortality are all consistent 
with differences in practice regarding screening, community testing and admission 
policies. 
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INTRODUCTION 
The current Covid-19 pandemic has been the subject of more open and rapid 
availability of data than any previous disease.  This has, inevitably, led to international 
comparisons of the spread and outcome of the disease, with widespread media 
speculation regarding the apparent differences in mortality between similar European 
countries.  On the face of it, the differences are stark.  On 2nd April 2020, Germany 
reported 85,063 confirmed cases with 1,111 deaths (1.3%), whereas three days earlier 
the comparable figures from Spain had shown 7,716 deaths from 87,956 confirmed 
cases (8.8%) and three days before that Italy had reported 9,134 deaths from 86,498 
cases (10.1%).[1]  While these may relate to differences in demographics, treatment or 
healthcare policy, the apparent mortality may also be altered by differences in testing 
policy and in changes in the rate of spread brought about by social distancing policies.  
In estimating mortality in the early stages of a rapidly spreading infection there are 
important potential confounding factors.  Early under-ascertainment with a failure to 
identify mild, moderate or asymptomatic cases in the community, may lead to an 
overestimate of mortality.  Conversely, the rapid rise in identified cases with unknown 
outcomes may lead to an underestimate as confirmed cases are identified a considerable 
time before deaths occur (right-censoring).  This paper describes a simulation model of 
the effect of different testing regimes on the apparent mortality in the early stages of 
exponential spread of a pandemic, and compares this to reported international variation 
in mortality rates for Covid-19. 
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METHOD 
An individual patient level simulation model was developed in R (R Foundation for 
Statistical Computing, Vienna) to consider the effects of different testing policies, 
spread parameters and hospital admission rates on the apparent mortality of a pandemic 
in the early phase of exponential spread. A series of testing scenarios were considered: 
x Testing restricted to those admitted to hospital with severe disease.
x The addition of community testing for virus in a proportion of symptomatic
patients.  Scenarios considered testing rates of 10%, 25%, 50%, 75% and 90%.
x Active tracing of known contacts and testing to identify symptomatic and
asymptomatic infections.
The first 19 doubling cycles of spread were considered, resulting in over 500,000 
simulated cases.  Apparent mortality for each testing scenario was estimated, based 
upon averaging 100 iterations to allow for Monte Carlo error, using a common seed to 
provide consistency across model runs.  Model estimates under the different scenarios 
were compared to the apparent mortality rates based upon published national data, for 
those countries with the greatest number of reported cases of Covid-19.  The structure 
of the model is shown diagrammatically in Figure 1. 
Figure 1.  Structure of the simulation model for Covid-19. 
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Parameters and assumptions 
A summary of the base case estimates for the required parameters, ranges used in the 
sensitivity analyses, and sources of data are provided in Table 1.   
Infection fatality rate (IFR) 
There is considerable doubt about the underlying IFR of Covid-19.  The apparent case 
fatality rate based upon reported deaths[1] is around 4.8% and an estimate based upon 
completed cases from China suggests a figure of 2.3%.[2]  Assumptions regarding 
asymptomatic or untested cases result in very much lower estimates for IFR that have 
been used in previous models.[3] For the base case in this study a published estimate 
of 0.66%[4] was used, with sensitivity analysis covering a wide range from 0.2% to 
4.8%.[5] 
Rate of spread 
The rate of spread was assumed to be exponential in the early stages and expressed in 
terms of days required for numbers to double, with a base case estimate of six days and 
range from 2 to 10 days.[1] 
Rate of hospital admission 
The rate of hospital admission was modelled as a multiple of the number of deaths. 
This was chosen as it is a figure that can be rapidly and more accurately ascertained 
from local data, whereas the actual admission rate as a proportion of infected cases is 
uncertain due to unknown incidence in the community.  In the early data from China 
the overall admission rate was approximately eight patients for every death.[6]  
However, these data include a significant proportion of patients with mild/moderate 
disease, who may have been admitted for isolation.  Estimates based upon only severe 
and critical cases put the ratio at nearer to 4.[7]   
Delay from onset to admission and admission to fatality 
The distribution of time intervals between onset of symptoms and hospital admission 
and between admission and death were obtained from models based upon the Chinese 
data.[4]  Separate estimates were provided for survivors and non-survivors; however, 
it seems likely that the survivor data is distorted by those with less severe disease, who 
may have been admitted early for isolation.[8]  Thus, for the base case, the time from 
onset to admission for all cases was based upon the non-survivor data.  Sensitivity 
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analysis included the full range reported for both groups.  The time from admission to 
death was based upon the modelled distributions from same data.[4] 
Proportion of asymptomatic cases 
The proportion of infections that remain asymptomatic is unknown, but has been 
estimated at 17.9% from the screened populations aboard the Diamond Princess cruise 
ship[9] and at 33%, based on Japanese nationals evacuated from Wuhan.[10] 
Table 1. Parameter values used in the base case analysis and sensitivity analysis. 
Parameter Base case Sensitivity analysis Source 
Underlying IFR 0.66% 0.2% to 5% [1, 2, 4, 5] 
Proportion that are 
severe/critical requiring 
admission 
9.2% 4.6% to 18.4% [2, 7] 
Days (IQR) onset to 
admission 
5.3 1.9 to 6.8 [4] 
Days (IQR) admission to 
death 
9.1 6.7 to 13.7 [4] 
Asymptomatic proportion 17.9% 7.7%-53.5% [9, 10] 
Doubling time (days) 6 2 to 10 [1] 
Testing policy 50% of 
community 
cases 
0 to 90% of 
community cases and 
contact tracing 
Scenario 
analysis 
Infections identifiable 
through contact tracing 
50% 20% to 80% Assumption 
Testing regimes 
It is assumed that all hospitalised patients will be tested.  Various scenarios have been 
considered with 10% to 90% of symptomatic cases in the community being tested.  In 
addition, a policy of tracing and testing known contacts has been considered.  In this 
6 
scenario it is assumed that asymptomatic cases would not otherwise have been 
identified and symptomatic cases will be identified two days earlier than would 
otherwise have been the case.  The proportion of infections that are amenable to 
identification through contact tracing is dependent upon the local circumstances.  Under 
strict lock-down it might be expected that most contacts would be identifiable, whereas 
with free movement on public transport this may be impossible.  Thus, an assumption 
of 50% was made with minimum and maximum values of 20% and 80%. 
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RESULTS 
Under the base case assumptions, the apparent mortality estimated from confirmed 
cases and known deaths is 5.3% with the assumption of 50% community testing of 
symptomatic patients, and ranges from 10.5%, if testing is restricted to hospitalised 
patients, down to 0.4% with intensive contact tracing and community testing (Table 2).  
Figure 2 illustrates the one-way sensitivity analysis of the key parameters as specified 
in Table 1 (see Appendix 1 for the full results of sensitivity analysis).  The rate of 
community testing and the ratio of hospitalised patients have the greatest effect and are 
considered in a two-way sensitivity analysis (see Table 2). 
Figure 2. Tornado diagram of the results of a one-way sensitivity analysis based upon 
the parameter ranges in Table 1.  The vertical line represents the base case (5.3%). 
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Table 2. Two-way sensitivity analysis of testing intensity and ratio of hospitalised to 
fatal cases (base case in bold) in relation to apparent mortality. 
Ratio of hospitalised to fatal cases 
Testing intensity 2.2:1 3:1 4:1 5:1 6:1 7:1 8:1 
Only hospitalised cases 18.9% 13.9% 10.4% 8.3% 7.0% 6.0% 5.2% 
Hospitalised and 10% of 
community cases 17.0% 12.5% 9.4% 7.5% 6.3% 5.4% 4.7% 
Hospitalised and 25% of 
community cases 14.2% 10.5% 7.8% 6.3% 5.3% 4.5% 3.9% 
Hospitalised and 50% of 
community cases 9.5% 7.1% 5.3% 4.3% 3.6% 3.1% 2.7% 
Hospitalised and 75% of 
community cases 4.9% 3.6% 2.7% 2.2% 1.9% 1.6% 1.4% 
Hospitalised and 90% of 
community cases 2.1% 1.6% 1.2% 1.0% 0.9% 0.8% 0.7% 
90% of community cases 
and 20% identified contact 
tracing 1.7% 1.3% 1.0% 0.8% 0.7% 0.7% 0.6% 
90% of community cases 
and 50% identified contact 
tracing 1.1% 0.9% 0.7% 0.6% 0.5% 0.5% 0.4% 
90% of community cases 
and 80% identified contact 
tracing 0.5% 0.4% 0.3% 0.3% 0.3% 0.3% 0.2% 
The apparent fatality rates from Covid-19 in those countries with the greatest number 
of cases is shown in Figure 3, with the modelled estimates different community testing 
regimes.   
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Figure 3. Apparent fatality rate from Covid-19 for 24 days after the first 10 deaths were 
reported in those countries with the highest reported rates, compared to  modelled 
apparent mortality with differing rates of community testing. 
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DISCUSSION 
The modelling demonstrates that the large differences between countries in apparent 
Covid-19 mortality rates are compatible with the effects that might be expected with 
different testing policy in the early stages of a pandemic.  While it is not possible to 
rule out differences in outcome due to demographic factors or aspects of the provision 
of health services, care is needed in drawing conclusions about such differences.  The 
effects of more stringent testing regimes and tighter hospital admission policies are 
likely to exaggerate apparent fatality rates.  High pressure on services, due to rapidly 
increasing demands, may affect both of these through limitations in staff, equipment 
and test kits for community testing as well as increasing the threshold of severity for 
hospital admission.  Paradoxically, since the effect of incomplete case ascertainment is 
partly counter-balanced by the effect of right-censoring, successful attempts at 
suppression, which reduce the impact of right-censoring, may appear to exaggerate 
estimates of mortality. 
It has been suggested that the use of historical numbers of confirmed cases, 14 days 
prior to fatality rates, as the denominator may provide more accurate estimates than 
basing rates on the most recent deaths and confirmed cases.[11]  Due to the skewed 
distribution of survival a more sophisticated estimate may be obtained by using 
weighted averages over a longer period.  However, neither of these would account for 
the other factors described, such as under-ascertainment, that might distort estimates in 
the opposite direction. 
Sensitivity analysis suggests that the underlying IFR has relatively little effect on 
apparent mortality, since the uncertainty largely relates to the number of asymptomatic 
or mild cases that remain unidentified.  Conversely, this implies that the IFR will remain 
uncertain, as demonstrated by the widely differing estimates,[4] until the result of more 
extensive population testing become available.  Another implication is that it is likely 
that those countries reporting higher mortality rates have a large number of unidentified 
cases and there is an urgent need to improve our understanding of this in order to predict 
future trends and the effects of suppression measures.  If the apparent differences 
between German and Italian mortality were to be entirely related to differences in 
admission and testing criteria, then the implication is that there were at least one million 
unconfirmed infections in Italy by 30 March 2020. 
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As with any modelling, this study is limited by the available information, but the 
general findings remain robust across a range of sensitivity analyses.  Some of the 
parameters and assumptions are based upon very limited data in selected populations, 
such as specific nations and cruise ship passengers, and may not be representative of 
the wider populations.  There may also be some concerns about the accuracy of reported 
data and, in particular, the reported deaths are largely based upon hospital admissions, 
whereas there may be a significant mortality amongst untested people in  care homes 
and other settings that are excluded from the data.  
In conclusion, this study demonstrates the potential dangers of speculation and over-
interpretation of apparent differences in mortality, without adjustment for differences 
in testing policy, admission rates and rate of spread.   It also provides a basis for 
understanding the likely effects of these differences in practice on reported mortality 
rates.  
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Appendix 1: Results of sensitivity analysis 
Case DT IFR As AR TTA TTD S1 S2 S3 S4 S5 S6 S7 S8 S9 
Doubling time 2 days 2 0.0066 0.179 4 5.3 9.1 4.7% 4.2% 3.5% 2.4% 1.2% 0.5% 0.4% 0.3% 0.1% 
Doubling time 3 days 3 0.0066 0.179 4 5.3 9.1 6.4% 5.7% 4.8% 3.2% 1.7% 0.7% 0.6% 0.4% 0.2% 
Doubling time4 days 4 0.0066 0.179 4 5.3 9.1 7.9% 7.1% 5.9% 4.0% 2.1% 0.9% 0.7% 0.5% 0.2% 
Doubling time 5 days 5 0.0066 0.179 4 5.3 9.1 9.2% 8.3% 7.0% 4.7% 2.4% 1.1% 0.9% 0.6% 0.3% 
Doubling time 6 days (base case) 6 0.0066 0.179 4 5.3 9.1 10.5% 9.4% 7.9% 5.3% 2.8% 1.2% 1.0% 0.7% 0.4% 
Doubling time 7 days 7 0.0066 0.179 4 5.3 9.1 11.4% 10.3% 8.6% 5.8% 3.0% 1.4% 1.1% 0.8% 0.4% 
Doubling time 8 days 8 0.0066 0.179 4 5.3 9.1 12.3% 11.1% 9.3% 6.3% 3.3% 1.5% 1.2% 0.8% 0.4% 
Doubling time 9 days 9 0.0066 0.179 4 5.3 9.1 13.1% 11.8% 9.9% 6.7% 3.5% 1.6% 1.3% 0.9% 0.5% 
Doubling time 10 days 10 0.0066 0.179 4 5.3 9.1 13.7% 12.3% 10.3% 7.0% 3.7% 1.6% 1.4% 0.9% 0.5% 
Low asymptomatic rate 6 0.0066 0.077 4 5.3 9.1 10.5% 9.4% 7.9% 5.3% 2.8% 1.2% 1.0% 0.7% 0.3% 
Higher asymptomatic rate 6 0.0066 0.535 4 5.3 9.1 10.4% 9.4% 7.9% 5.4% 2.9% 1.4% 1.1% 0.7% 0.4% 
Low admission rate (2.2) 6 0.0066 0.179 2.2 5.3 9.1 18.9% 17.0% 14.2% 9.5% 4.9% 2.1% 1.7% 1.1% 0.5% 
Admission rate 3 6 0.0066 0.179 3 5.3 9.1 13.9% 12.5% 10.5% 7.1% 3.6% 1.6% 1.3% 0.9% 0.4% 
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Admission rate 5 6 0.0066 0.179 5 5.3 9.1 8.3% 7.5% 6.3% 4.3% 2.2% 1.0% 0.8% 0.6% 0.3% 
Admission rate 6 6 0.0066 0.179 6 5.3 9.1 7.0% 6.3% 5.3% 3.6% 1.9% 0.9% 0.7% 0.5% 0.3% 
Admission rate 7 6 0.0066 0.179 7 5.3 9.1 6.0% 10.5% 4.5% 3.1% 1.6% 0.8% 0.7% 0.5% 0.3% 
Highest admission rate 6 0.0066 0.179 8 5.3 9.1 5.2% 4.7% 3.9% 2.7% 1.4% 0.7% 0.6% 0.4% 0.2% 
Low Time to death 6 0.0066 0.179 4 5.3 6.7 12.9% 11.6% 9.7% 6.6% 3.4% 1.5% 1.2% 0.8% 0.4% 
High Time to death 6 0.0066 0.179 4 5.3 13.7 7.3% 6.6% 5.5% 3.7% 1.9% 0.9% 0.7% 0.5% 0.2% 
Low Time to admission 6 0.0066 0.179 4 1.9 9.1 11.0% 9.9% 8.3% 5.6% 3.0% 1.4% 1.1% 0.8% 0.4% 
High Time to admission 6 0.0066 0.179 4 6.8 9.1 10.3% 9.3% 7.8% 5.2% 2.7% 1.2% 1.0% 0.6% 0.3% 
Low IFR 6 0.002 0.179 4 5.3 9.1 10.4% 9.4% 7.8% 5.3% 2.7% 1.1% 0.9% 0.6% 0.3% 
Intermediate IFR 6 0.004 0.179 4 5.3 9.1 10.4% 9.4% 7.8% 5.3% 2.7% 1.1% 0.9% 0.6% 0.3% 
High IFR 6 0.023 0.179 4 5.3 9.1 10.4% 9.5% 8.0% 5.6% 3.1% 1.7% 1.4% 1.1% 0.7% 
Maximum IFR 6 0.048 0.179 4 5.3 9.1 10.4% 9.5% 8.2% 5.9% 3.7% 2.4% 2.1% 1.7% 1.2% 
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Parameters 
DT Doubling time (days) 
IFR Infection fatality rate 
As Proportion asymptomatic 
AR Admission rate (multiplier for IFR) 
TTA  Time from onset to admission 
TTD Time from admission to death 
Scenarios 
S1 Testing only admitted cases 
S2 Testing all admitted cases and 10% of symptomatic cases 
S3 Testing all admitted cases and 25% of symptomatic cases 
S4 Testing all admitted cases and 50% of symptomatic cases 
S5 Testing all admitted cases and 75% of symptomatic cases 
S6 Testing all admitted cases and 90% of symptomatic cases 
S7 Testing all admitted cases, 90% of symptomatic cases and 20% identification through contact tracing 
S8 Testing all admitted cases, 90% of symptomatic cases and 50% identification through contact tracing 
S9 Testing all admitted cases, 90% of symptomatic cases and 80% identification through contact tracing 
Base case highlighted 
